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Introduction
The current COVID-19 pandemic influences many areas of social life, medical treatments 
and the way allergy is performed. Allergen-specific immunotherapy (AIT) is one of the 
most important treatment options for IgE-mediated allergies and is based on 
immunological effects on the diseased patient. This manuscript outlines the EAACI 
recommendations regarding AIT during the COVID-19 pandemic and aims at supporting 
allergists and all physicians performing AIT in their current daily practice with clear 
recommendations how to perform treatment during the pandemic and in SARS-CoV-2 
infected patients.
Coronavirus disease 2019 (COVID-19) 
The World Health Organization (WHO), on March 11, 2020, declared a pandemic of an 
infectious disease recently referred to as “coronavirus disease 2019” (COVID-19). 
Currently, COVID-19 is fast spreading across the globe. COVID-19 is caused by a novel 
strain of human coronaviruses, the severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), named by the International Committee on Taxonomy of Viruses (ICTV). 
SARS-CoV-2 was first detected in a cluster of patients with pneumonia in December 
2019 in Wuhan, China(1, 2). SARS-CoV-2 is a Betacoronavirus of the subgenus 
Sarbecovirus and the subfamily Orthocoronavirinae. It can be isolated from human 
samples obtained from respiratory secretions, nasal and pharyngeal smears and isolated 
on cell cultures(1, 2). SARS-CoV-2 is the 7th member of the coronavirus family able to 
infect humans. It differs from the Middle East Respiratory Syndrome Coronavirus (MERS-
CoV), the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), and viruses 
responsible for the common cold (229E, OC43, NL63, and HKU1)(3). Coronaviruses are 
zoonotic, i.e. they can be transmitted between animals and humans.
COVID-19 presents with many different clinical manifestations, ranging from 
asymptomatic cases to mild and severe disease, with or without pneumonia(4).  
Common signs of COVID-19 are respiratory problems, fever, cough, shortness of breath 
and difficulties in breathing. Other signs of viral airway infection may include nasal 
symptoms and sore throat. In more severe cases, infection with COVID-19 can cause 
pneumonia, severe acute respiratory syndrome, kidney failure, and even death(4-8). In 
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diabetes mellitus, coronary artery disease and immunodeficiency of different origins are 
listed as risk factors for severe illnesses, hospitalization and death(4-6, 8).
As COVID-19 is caused by a newly identified viral strain, there are no therapeutics 
proved to be effective in clinical trials or vaccines, so far, and there is presumed to be no 
pre-existing immunity in the population(9). In most instances, coronaviruses are believed 
to be transmitted through large respiratory droplets from person to person, through 
inhalation or deposition on mucosal surfaces. Other routes implicated in the transmission 
of coronaviruses include contact with contaminated fomites and inhalation of aerosols 
produced during aerosol-generating procedures, such as sneezing or coughing. The 
SARS-CoV-2 virus has been detected in respiratory, faecal and blood specimens(10). 
The highest risk of healthcare-associated transmission occurs in the absence of standard 
precautions, when primary infection prevention and control measures for respiratory 
infections are not in place, and when handling patients whose COVID-19 diagnoses is yet 
to be confirmed. Since airborne transmission is possible, we recommend a cautious 
approach because of possible transmission through aerosols  (11, 12). 
More disease background information is available online from the European Centre for 
Disease Prevention and Control (ECDC)(13), WHO(14)) and the ECDC’s Rapid Risk 
Assessment(9).
Allergen-specific immunotherapy (AIT) 
AIT is the onlydisease-modifying therapy that confers a long-term clinical benefit for 
allergic airway diseases such as in allergic bronchial asthma or 
allergicrhinoconjunctivitisand other allergic conditions(15). Since its(16)emergence over 
hundred years ago (1911), AIT is an established and internationally recognized 
procedure for the causal treatment of immediate-type allergic reactions (type I 
allergy) and associated diseases.
AIT induces an immune tolerance responses against the allergen in sensitized  
patients(17). 
Systematic reviews and meta-analyses have confirmed that AIT is effective in reducing 
symptomstogether with rescue medication in patients with allergic asthma (18)and 
allergic rhinoconjunctivitis(19).
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immunotherapy (SLIT), liquid drops or tablets placed under the tongue(22).
Thereducedriskof developing asthma in patientswith allergic rhinitis is another advantage 
of AIT, that is still under debate but was demonstrated to be at least effective in the short 
term(23, 24). AIT is also effective in patients withIgE-mediated food allergy(23-26)and 
insect venom allergy(27).Moreover, analyses bythe European Academy of Allergy and 
Clinical Immunology (EAACI) demonstrated the cost-effectiveness of this disease-
modifying therapy option(28-30).
AIT and viral infections
Eventhough it is well established that allergic airway diseases are associated with an 
increased risk of infections, little is known about the potential influence of viral infections 
on AIT(31).
In a prospective and comparative clinical study, Ahmetaji et al.found no significant 
difference in the efficacy or in the improvement of symptoms of allergic asthma patients 
under subcutaneous allergen-specific immunotherapy with or without symptomatic 
influenza,nor in the standard chemical and haematology parameters and different 
cytokines during a one-year follow up(32). These preliminary data suggest that 
SCITininfluenzainfected patientswas safe and well-tolerated.
Iemoli et al. evaluated the safety and clinical effectiveness of sublingual grass tablet 
immunotherapy in a group of HIV-positive patients with allergic rhinitis under antiretroviral 
HIV therapy.HIV infection has been regarded to be a relative contraindication for AIT. 
Highly active antiretroviral treatment has improved the immune function and life 
expectancy in HIV-infected patients whose respiratory allergic incidence is similar to that 
of the general population(33). Clinical efficacy data showed a significant improvement in 
SLIT-treated patients compared to controls but not any considerable alteration of 
peripheral T CD4 lymphocyte cell counts and HIV viral load in both groups. These data 
showthat SLIT therapy in viro-immunological controlled HIV positive patients was 
efficacious, safe and well-tolerated. 
Cytomegalovirus (CMV) was shown to enhance the allergenic potential of otherwise 
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to CMV and ovalbumin (OVA)(34). In contrast, immune reactions to Virus-like-particles 
(Vlp) may enforce the immune responses in AIT and may even be used as AIT adjuvants 
for inhalational and food (peanut) allergen in the near future(35, 36).
With the limited experimental data available so far, it seems that patients with allergic 
rhinitis did not develop additional distinct symptoms and more severe courses than other 
patients(4). Allergic children showed a mild course, similar to other children(4).
Immune mechanisms in AIT and COVID-19 – differences and similarities
AIT aims to induce allergen-specific immune tolerance in allergy patients by using 
multiple mechanisms including T cells, B cells, innately lymphoid cells (ILC) and effector 
cells, such as eosinophils, mast cells and basophils. One of the main changes is the 
development of a T and B regulatory cell response and their suppressive cytokines such 
as IL-10andTGF- and surface molecules such as CTLA-4 and PD1, all of which form a 
suppressive milieu(29, 37).This immune regulatory response is taking place in targeted 
antigen/allergen-specific T and B cells but does not affect the whole immune system and 
does not cause any systemic immune deficiency.  T cell responses in severe COVID-19 
are represented with lymphopenia that is mainly affecting memory T lymphocytes. Both 
CD4 and CD8 T cells decrease, however this change is more pronounced in CD8+ T 
cells. Cytotoxic T lymphocytes and NK cells in patients infected with SARS-CoV-2 are 
essential for an appropriate anti-viral response(38). A recent study suggests that patients 
show functional exhaustion of cytotoxic T lymphocytes associated with SARS-CoV-2 
infection. The total number of NK and CD8+ T cells was markedly decreased in patients 
with SARS-CoV-2 infection (38). This may cause a disruption of antiviral immunity and 
may play a role in the pathogenesis and severity ofCOVID-19.
AIT significantly decreases allergen-specific Th2 cells in circulation and reduces the 
general type2 response by decreasing Th2 cells and type 2 ILCs(39-41). COVID-19 does 
not significantly increase in severity in allergicpatients, with conditions such as rhinitis, 
urticaria and atopic dermatitis(4, 42).Ithas not been demonstrated if there is aswitch 
between TH1 and TH2 cellsin COVID-19, but there is developing data that disease 
severity is linked to a systemic Th1 response and inflammasome activation together with 
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severe COVID-19 cases and a major reason for acute respiratory distress syndrome 
(ARDS) and multi organ failure. Several levels of evidence suggest that the rapid COVID-
19 mortality might be due to a virus-activated “cytokine storm syndrome”(43).In a study of 
41 hospitalized patientswith high-levels of proinflammatory cytokines including IL-2, IL-7, 
IL-10, G-CSF, IP-10, MCP-1, MIP-1A, and TNFα were obsered in severe COVID-19 
cases(44).
AIT changes the cellular composition and inflammatory mediators in the affected 
organs, such as for examplesthe nose in allergic rhinitis(17). Eosinophils and their 
inflammatory mediators decrease in allergic rhinitis in the nose during AIT. In COVID-19, 
systemic eosinopenia was observed in 52.9% of the patients. Decreased blood 
eosinophil counts correlate positively with lymphocyte counts in severe (r=0.486, 
p<0.001) and non-severe (r=0.469, p<0.001) patients after hospital admission(4).The 
reasons and mechanisms of systemic eosinopenia remain to be investigated.
In AIT, reduced eosinophil counts and regulation of specific TH2 response is only seen 
after several years of continues therapy. This supports, that AIT is not going to interfere 
viral infections. AIT has a clear desensitization effect on effector cells. This effect is 
antigen specific and is acting early during the course of AIT. Mast cells are not 
considered to be relevant in viral infection response.
Allergen-specific antibody levels change in the course of AIT with decreased specific IgE 
in the long run and a relatively rapid increase in specific IgG1 and IgG4(29, 45). In 
COVID-19 like many viral infections SARS-CoV-2-specific IgM increases in the acute 
phase followed by specific IgG(46-48).
Overall, theCOVID-19 immunological mechanisms seem to be similar to SARS 
and MERS and also to severe influenza infections. An appropriate anti-viral immune 
response should develop with cytotoxic T cells and IgM and IgG antibodies, whereas a 
very strong uncontrolled immune response as in a cytokine storm, becomes detrimental 
(Table 1).
Table 1. Immunological characteristics of AIT and COVID-19.
Immunologic changes AIT COVID-19
T cell responses Suppression of TH2 cells, 
induction of Treg and TH1 cells
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CD8+ T cells There is nomajor change Severe lymphopenia is 
observed in CD8+ T cells
TH1-TH2 responses AIT decreases allergen-specific 
Th2 responses in circulation 
and in the affected organs such 
as in the nose
Severe disease shows a 
systemic severe inflammatory 
response with a cytokine storm
Eosinophils Decrease in their numbers and 
mediators in the nose
Systemic decrease in their 
numbers in more than half of 
the patients.
Specific antibody levels Allergen-specific IgE decreases 
in the late course, with an early 
increase in specific IgG4 
In the acute phase virus-
specific IgM increases followed 
by virus specific IgG during 
convalescence. 
Preventingin Allergy facilities and control measures in AIT 
We recommend using the infection prevention and control measures in any patient 
undergoing AIT according to ECDC and WHO. This implies that the recommended 
infection prevention and control measures of individual regions or countries should be 
followed, including those in this document and the procedures for reporting and transfer 
of persons under investigation and of probable/confirmed COVID-19 cases.
Those feeling ill with typical respiratory symptoms should be encouraged to contact 
healthcare services by telephone or E-Health/telemedicine/online to seek medical advice 
(13, 49)(triage). This will reduce the number of people with symptoms of COVID-19 that 
have contact with the Allergy centerhealthcare personnel(13, 49).
Allergy services and primary care staff, including physicians, nursing and administrative 
staff with patient contact, should be aware of the following: a) the current COVID-19 
epidemiologic situation in their country and globally, b) known risk factors for infections; 
c) clinical symptoms and signs of COVID-19; d) recommended infection prevention and 
control measures in their region or country, including those in this document; e) 
procedures for reporting and transfer of persons under investigation and of 
probable/confirmed cases.
Appropriate personal protective equipment (PPE) should be available onsite for all 
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In each Allergy facility, a dedicated member of staff (e.g. head doctor/nurse) should lead 
the COVID-19 preparedness and implement relevant infrastructure and control measure 
policies. 
Signs should beposted at all entrance doors listing the main symptoms compatible with 
COVID-19 (fever, cough and shortness of breath) and informing visitors with any of these 
symptoms not to enter theAllergy Unit. Everyone within the Allergy clinic and all those 
enteringthe practice should adopt appropriate hand hygiene measures, usingsoap and 
water, or an alcohol-based handrub.
Based on a case-by-case risk assessment, the use of PPE for AIT should be considered. 
With the current knowledge on the transmission of COVID-19, in which respiratory 
droplets seem to play a significant role (although airborne transmission cannot be ruled 
out at this stage), and taking into consideration the possible shortage of PPE in 
healthcare settings due to the increasing number of COVID-19 patients, the suggested 
set of PPE for droplet, contact and airborne transmission (gloves, goggles, gown and 
FFP2/FFP3 respirator) can be adapted for the clinical assessment of suspected COVID-
19 cases.If available, provide a surgical mask for patients with respiratory symptoms (e.g. 
cough)(50).
Healthcare workers performing aerosol-generating procedures (AGP), such as 
swabbing(50), should wear the suggested PPE set for the prevention of droplet, contact 
and airborne transmission (gloves, goggles, gown and FFP2/FFP3 respirator)(51).
To maximize the use of PPE if there is an insufficient supply, staff should be assigned to 
carry out procedures, or a procedure, in designated areas(52).
Managing AIT during the COVID-19 pandemic
AIT is a treatment, that requires recurrentdoctor/nurse/patient contact over a more 
extended period, e.g. 3 years.
In SCIT, injections are administered with daily, weekly (up dosing phase) or monthly 
(continuation phase) intervals. 
In SLIT, the initiation is given in allergy clinics or in a doctor´s office, while continuation is 
performed by patients themselves with regular control visits. 
Each SCIT or SLIT product needs approval by the competent authority. It must contain 
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most products authorized in Europe, instructions for use recommend that patients 
experiencing an acute respiratory tract infection should temporarily discontinue AIT 
treatment until the infection is resolved. We recommend taking similar action in COVID-
19. Confirmed cases should discontinue AIT, both SCIT or SLIT, independent ofdisease 
severity until the symptoms have completely resolved and/or an adequate quarantine has 
been performed. The possibility of expanding injection intervals in the continuation phase 
may be beneficial. In patients, who recovered from COVID-19 or who are found to have a 
sufficient SARS-CoV-2 antibody response after (asymptomatic) disease(14), AIT can be 
started or continued as planned. 
AIT can also be continued as usual in patients without clinical symptoms and signs of 
COVID-19 or other infections and without a history ofexposure ot SARS-CoV-2 or contact 
to COVID-19 confirmed individualswithin the past 14 days.
SLIT offers the possibility of taking it at home, thus avoiding the need to travel to or stay 
in an allergy clinic or doctor’s office, which would be associated with a risk of infection.
Recommendations in noninfected individuals during COVID-19 pandemics or 
recovered patients after COVID-19 infection
Interrupting subcutaneous immunotherapy is not advised. Especially in potentially life-threatening 
allergies, such as venom allergy, SCIT should be regularly continued. The possibility of expanding injection 
intervals in the continuation phase should be checked and may be beneficial.
Interrupting sublingual immunotherapy is not advised. Supply the patient with sufficient medication for a 
minimum of a 14 days quarantine. 
Sublingual immunotherapy can be taken at home. The intake of SLIT by the patient at home or any place is 
advantageous in avoiding contact to potentially infected persons.
Both subcutaneous and sublingual immunotherapy can be continued in the current COVID-19 pandemics, 
in any asymptomatic patients without suspicion for SARS-CoV-2 infection and/or contact to SARS-CoV-2 
positive individuals, in any patient withnegative test result (RT-PCR) or in any patient after an adequate 
quarantine or with detection of serum IgG to SARS-CoV 2 without virus-specific IgM.
Preparedness of your Allergy clinic is imperative to cope with COVID-19. Follow WHO guidelines and 
advice staff accordingly.









This article is protected by copyright. All rights reserved
regularly with incoming new information on COVID-19.
Recommendations in COVID-19 diagnosed cases or suspected for SARS-CoV-2 
infection
Interrupting subcutaneous immunotherapy is advised. 
Interrupting sublingual immunotherapy is advised. 
Both subcutaneous and sublingual immunotherapy should be discontinued in symptomatic patients with 
exposure or contact to SARS-CoV-2 positive individuals, or patients with positive test results (RT-PCR).
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